ABOUT VISTA PARTNERS

Vista Partners offers free, exclusive insight and research on the Dow 30 and Select Emerging Growth companies....

Browse Latest Coverage Learn More

Stay informed. Stay Competitive.

Vista Partners offers an exclusive newsletter and content with daily, weekly, monthly, and quarterly investing ideas, strategies, and market insights.





We value your privacy and will never share your information. Click here to learn more about all the great features offered in our newsletter.

The Latest

Vista Current Coverage

San Diego-based Fate Therapeutics Enters Strategic Collaboration with Tokyo’s ONO Pharmaceutical Co.

San Diego-based Fate Therapeutics (Nasdaq: FATE) is a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders. The Company is pioneering the development of off-the-shelf cell therapies using its proprietary induced pluripotent stem cell (iPSC) product platform. The Company’s immuno-oncology...

Have You Read “Vista Partners Weekly Market Update 9-15-18?”

Vista Partners published “Vista Partners Weekly Market Update 9-15-18!”  Each weekly issue is written by Vista Partners’ Managing Director, John Heerdink! Each weekly issue includes updates on the stock market, a “Stocks To Watch” section, & featured daily stories & videos from Vista’s Coverage Universe of...

Will You Be One Of The First To Get Apple’s New iPhone Xs?

Dow 30 component Apple (AAPL) revolutionized personal technology with the introduction of the Macintosh in 1984. Today Apple leads the world in innovation with iPhone, iPad, Mac, Apple Watch and Apple TV. Apple’s four software platforms — iOS, macOS, watchOS, and tvOS — provide seamless...

Dow 30

22,350
close
+0.4%
Week
+13.1%
YTD

Dow 30

22,350
close
+0.4%
Week
+13.1%
YTD

Dow 30

22,350
close
+0.4%
Week
+13.1%
YTD

Dow 30

22,350
close
+0.4%
Week
+13.1%
YTD

Dow 30

22,350
close
+0.4%
Week
+13.1%
YTD